Daptomycin

Restricted
Restricted

C. diff Risk

Low

Oral Bioavailability

NA

Approximate Cost

Dosing

4-6 mg/kg IV q24h

General Information

Common Usage

Targeted therapy of resistant gram positive infections with MRSA (particularly when MIC>=2) and VRE including endovascular infection.

Drug Monitoring

Creatine kinase weekly.

Adverse Effects

Myopathy including rhabdomyolysis, GI side effects common, rash, phlebitis, increased INR.

Major Interactions

Statins and fibrates: monitor creatine kinase or hold while on daptomycin therapy (increased myopathy).

Additional Information

Infectious Disease consultation recommended.

Inactivated by pulmonary surfactant and therefore insufficient for pulmonary infection.

Pharmacology

Antimicrobial class: Cyclic lipopeptide, depolarizes bacterial cell membrane

Pregnancy category: B